Increasing Prevalence Of Autoimmune Diseases Fueling The Growth Of The Market Due To Its Association With Immune System Dysregulation Continues To Impact The Growth Of The Lichen Planus Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Lichen Planus Market In 2026 And 2030?

The market size for lichen planus has shown robust growth in recent years. Its valuation is projected to rise from $1.26 billion in 2025 to $1.35 billion in 2026, advancing at a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this historical expansion include a rise in the diagnosis of autoimmune skin disorders, the accessibility of corticosteroid therapies, the proliferation of dermatology specialty clinics, enhanced clinical understanding of lichen planus, and the adoption of phototherapy techniques.

The lichen planus market is projected for robust expansion in the coming years. It is anticipated to reach $1.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This expansion over the forecast period is due to factors such as increased demand for cutting-edge immunotherapies, a heightened emphasis on sustained symptom management, the broadening of biologic treatment investigations, greater incorporation of digital dermatology instruments, and innovations in specific anti-inflammatory medications. Key developments expected during this period involve the rising uptake of targeted immunomodulatory treatments, an increase in the application of combined topical and systemic therapies, a reinforced focus on the management of chronic conditions, the growth of individualized dermatology services, and enhanced patient awareness and disease tracking.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24279&type=smp

Which Strategic Drivers Are Supporting The Lichen Planus Market Development?

A future expansion of the lichen planus market is anticipated, driven by the rising occurrence of autoimmune diseases. These conditions involve the immune system erroneously targeting healthy cells within the body, and include examples like rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The growing incidence of autoimmune diseases is linked to genetic predispositions, where particular gene variations affect immune system function and lead to connective tissue irregularities. This uptick in autoimmune disease cases not only highlights a wider issue in immune regulation but also contributes to a greater frequency of lichen planus occurrences. For example, as reported in June 2024 by the Australian Institute of Health and Welfare, an Australian government agency, around 514,000 (2.0%) individuals had rheumatoid arthritis in 2022. This condition accounted for 2.0% of the overall disease burden and 16% of the musculoskeletal conditions burden in 2023, with 1,322 deaths (5.1 deaths per 100,000 population) documented in 2022, representing 0.7% of all fatalities. Consequently, the expanding occurrence of autoimmune diseases is a key factor boosting the lichen planus market’s expansion.

What Are The Major Segment Categories Within The Lichen Planus Market?

The lichen planus market covered in this report is segmented –

1) By Disease Type: Lichen Planus, Oral Lichen Planus, Genital Lichen Planus, Lichen Planus Pigmentosus

2) By Treatment Type: Topical Therapies, Systemic Therapies, Phototherapy

3) By Route Of Administration: Topical, Oral, Intravenous

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Lichen Planus: Papular Lichen Planus, Hypertrophic Lichen Planus, Actinic Lichen Planus, Linear Lichen Planus, Annular Lichen Planus

2) By Oral Lichen Planus: Reticular Oral Lichen Planus, Erosive Oral Lichen Planus, Atrophic Oral Lichen Planus, Plaque-Like Oral Lichen Planus, Bullous Oral Lichen Planus

3) By Genital Lichen Planus: Erosive Genital Lichen Planus, Papular Genital Lichen Planus, Annular Genital Lichen Planus, Vulvovaginal-Gingival Syndrome

4) By Lichen Planus Pigmentosus: Diffuse Lichen Planus Pigmentosus, Blotchy Lichen Planus Pigmentosus, Linear Lichen Planus Pigmentosus, Perifollicular Lichen Planus Pigmentosus, Flexural Lichen Planus Pigmentosus

What Trends Are Impacting The Lichen Planus Market?

Leading companies within the lichen planus market are concentrating on creating innovative solutions, such as liposomal formulations, to enhance targeted drug delivery and minimize systemic side effects. These liposomal formulations represent drug delivery systems in which active ingredients are encased within liposomes, which are small spherical vesicles made of lipid bilayers that improve drug stability, increase absorption, and facilitate targeted delivery with reduced systemic side effects. For example, in February 2025, Lipella Pharmaceuticals Inc., a US-based biotechnology company specializing in therapies for serious diseases, secured US Food and Drug Administration approval for an expanded access program (EAP) for LP-310. LP-310 is a liposomal formulation of tacrolimus specifically designed to provide targeted relief for oral lichen planus (OLP) patients, while concurrently reducing systemic exposure. This program enables patients facing serious or life-threatening conditions with unmet medical needs to access treatments beyond clinical trials before their official approval.

Which Companies Are Engaged In The Lichen Planus Market Environment?

Major companies operating in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, Lipella Pharmaceuticals Inc.

Access The Complete Lichen Planus Market Report:

https://www.thebusinessresearchcompany.com/report/lichen-planus-global-market-report

Which Region Is The Primary Market For The Lichen Planus Market?

North America was the largest region in the lichen planus market in 2025. The regions covered in the lichen planus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Lichen Planus Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/lichen-planus-global-market-report

Browse Through More Reports Similar to the Global Lichen Planus Market 2026, By The Business Research Company

Luxury Skincare Market Report 2026

https://www.thebusinessresearchcompany.com/report/luxury-skincare-global-market-report

Liraglutide Market Report 2026

https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

Sugar And Confectionery Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/sugar-and-confectionery-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795